FutureGen Biopharmaceutical (Beijing) Co., Ltd

3 in Phase 3

Quick facts

Phase 3 pipeline

FG-M108 · Oncology
FG-M108 is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity.
M108 monoclonal antibody · Oncology
M108 is a monoclonal antibody that targets a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity or block pathogenic signaling.
Placebo for FG-M108
This is a placebo, meaning it has no active therapeutic effect.

Phase 1 pipeline

M108

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about FutureGen Biopharmaceutical (Beijing) Co., Ltd

What is FutureGen Biopharmaceutical (Beijing) Co., Ltd's pipeline?

FutureGen Biopharmaceutical (Beijing) Co., Ltd has 3 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include FG-M108, M108 monoclonal antibody, Placebo for FG-M108.

Sector hub: All tracked pharma companies